Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May 11;13(1):2583.
doi: 10.1038/s41467-022-29911-3.

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Pere Millat-Martinez #  1   2 , Arvind Gharbharan #  3 , Andrea Alemany #  1   4   5 , Casper Rokx  3 , Corine Geurtsvankessel  6 , Grigorios Papageorgiou  7 , Nan van Geloven  8 , Carlijn Jordans  3 , Geert Groeneveld  9 , Francis Swaneveld  10 , Ellen van der Schoot  11 , Marc Corbacho-Monné  1   5   12 , Dan Ouchi  1   13 , Francini Piccolo Ferreira  14 , Pierre Malchair  15 , Sebastian Videla  1   16   17 , Vanesa García García  15 , Anna Ruiz-Comellas  18   19   20 , Anna Ramírez-Morros  18 , Joana Rodriguez Codina  21 , Rosa Amado Simon  21 , Joan-Ramon Grifols  4   22 , Julian Blanco  23 , Ignacio Blanco  4   24 , Jordi Ara  4   25 , Quique Bassat  2   26   27   28   29 , Bonaventura Clotet  1   4   20   23 , Bàrbara Baro  2 , Andrea Troxel  30 , Jaap Jan Zwaginga  31   32 , Oriol Mitjà  1   4   20   33 , Bart J A Rijnders  34 ; CoV-Early study group; COnV-ert study group
Collaborators, Affiliations
Meta-Analysis

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Pere Millat-Martinez et al. Nat Commun. .

Erratum in

  • Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.
    Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageorgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monné M, Ouchi D, Piccolo Ferreira F, Malchair P, Videla S, García García V, Ruiz-Comellas A, Ramírez-Morros A, Rodriguez Codina J, Amado Simon R, Grifols JR, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitjà O, Rijnders BJA; CoV-Early study group; COnV-ert study group. Millat-Martinez P, et al. Nat Commun. 2024 May 22;15(1):4352. doi: 10.1038/s41467-024-48645-y. Nat Commun. 2024. PMID: 38778041 Free PMC article. No abstract available.

Abstract

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data meta-analysis was implemented. Outpatients aged ≥50 years and symptomatic for ≤7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution.

Trial registration: Clinicaltrials.gov NCT04621123 and NCT04589949.

Registration: NCT04621123 and NCT04589949 on https://www.

Clinicaltrials: gov.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. CONSORT flow diagram.
Figure shows the CONSORT flow diagram of the COMPILEhome patients. 833 patients were screened at a study site and 782 were included for analysis.
Fig. 2
Fig. 2. Distribution for COVID-19 severity at 28 days.
CP Convalescent plasma. Figure shows the distribution of the outcome of the patients in the 28 days after inclusion across the 5-point disease severity scale: 1 = recovered before day 8 after transfusion, 2 = continued symptoms after day 7, 3 = hospital admission, 4 = invasive ventilation, 5 = death. Moving from lighter to darker shading represents increasing scores on the severity scale. The darker shade includes point 4 and 5 of the scale (invasive ventilation or death).
Fig. 3
Fig. 3. Time to full symptom resolution up to day 28 (end of follow-up).
CP Convalescent plasma. Log-rank test p = 0.66. The dotted error bars represent the 95% CI.
See this image and copyright information in PMC

References

    1. Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Brown MJ, Alazawi W, Kanoni S. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 2021;385:1147. doi: 10.1056/NEJMc2108482. - DOI - PubMed
    1. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet397 1637–1645 (2021). - PMC - PubMed
    1. Dougan M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med. 2021;385(Oct):1382–1392. doi: 10.1056/NEJMoa2102685. - DOI - PMC - PubMed
    1. Gottlieb RL, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325:632–644. doi: 10.1001/jama.2021.0202. - DOI - PMC - PubMed

Publication types

Associated data